Multiple System Atrophy (MSA) represents a unique neurodegenerative disorder characterized by primary involvement of oligodendrocytes rather than neurons. This page provides an integrated overview of the pathophysiological mechanisms that drive disease onset and progression, from molecular events to network-level dysfunction.
MSA is fundamentally distinct from other α-synucleinopathies in that oligodendrocytes are the primary affected cell type:
- GCI dominance: Glial cytoplasmic inclusions far outnumber neuronal inclusions
- Early involvement: GCI formation precedes significant neuronal loss
- Myelin dysfunction: Oligodendrocyte failure drives secondary neurodegeneration
[Wenning2009/https://doi.org/10.1002/ana.21535)
flowchart TD
subgraph Primary Event
A["Oligodendrocyte dysfunction"] --> B["GCI formation"]
end
subgraph Secondary Events
B --> C["Myelin breakdown"]
C --> D["Neuronal dysfunction"]
D --> E["Network degeneration"]
end
subgraph Clinical Outcome
E --> F["Motor symptoms"]
E --> G["Autonomic failure"]
E --> H["Cerebellar dysfunction"]
end
Key Features:
- Pathological α-synuclein with Ser129 phosphorylation
- Filament structure differs from Lewy bodies
- GCI-specific composition
Aggregation Mechanisms:
- Nuclear inclusions in oligodendrocytes
- Seeding from neuronal sources
- Impaired clearance systems
Early Event:
- Myelin protein alterations precede GCI formation
- Metabolic compromise of oligodendrocytes
- Vulnerable regions: cerebellar peduncles, basal ganglia
Consequences:
- Axonal metabolic support failure
- Conduction deficits
- Secondary axonal degeneration
[Jellinger2023/https://doi.org/10.1007/s00401-023-02567-4)
Basal Ganglia Networks:
- Striatal output disruption
- Motor pattern generator dysfunction
- Contributes to parkinsonism
Brainstem Networks:
- Autonomic centers involvement
- Sleep-wake regulation disruption
- Oculomotor abnormalities
Cerebellar Networks:
- Cerebellothalamic pathway involvement
- Coordination deficits
- Gait and balance impairment
Prion-Like Spreading:
- Intercellular transmission of pathology
- Neuron-to-oligodendrocyte spread
- Region-to-region progression
[Braak2007/https://doi.org/10.1016/j.neurobiolaging.2006.02.002)
- Impaired autophagy-lysosome system
- Proteasomal dysfunction
- Metabolic vulnerability
- Oxidative stress susceptibility
- Axonal transport disruption
- Synaptic dysfunction
- Energy failure
- Calcium dysregulation
- Astrocyte reactivity
- Microglial activation
- Neuroinflammation amplification
¶ Staging and Progression
- Stage 1: Localized GCI formation
- Stage 2: Regional spread
- Stage 3: Widespread involvement
- Stage 4: End-stage disease
- Early: Autonomic symptoms
- Mid: Motor symptoms emerge
- Late: Severe disability
- Oligodendrocyte protection
- α-Synuclein clearance
- Myelin maintenance
- Network stabilization
- Disease-modifying therapies
- Symptomatic management
- Supportive care
- Elevated CSF α-synuclein oligomers
- Reduced CSF α-synuclein levels
- Neurofilament light chain (NfL) as progression marker
- Imaging: hot cross bun sign in pons
- GCI in oligodendrocytes with tubulin-like filaments
- Neuronal loss in striatum, brainstem, cerebellum
- Myelin degeneration in white matter
- Astroglial and microglial activation
- α-Synuclein aggregation inhibitors
- Myelin stabilization compounds
- Oligodendrocyte progenitor cell (OPC) activation
- Autophagy enhancers
- Minocycline trials (neuroprotection)
- Mesenchymal stem cell therapy
- Immunotherapy approaches
Oxidative stress plays a central role in MSA pathogenesis, arising from multiple sources including mitochondrial dysfunction, iron accumulation, and neuroinflammation. The brain's high oxygen consumption and limited antioxidant capacity make it particularly vulnerable to oxidative damage. In MSA, several converging pathways lead to excessive reactive oxygen species (ROS) generation [Song et al., 2023].
Sources of Oxidative Stress:
- Mitochondrial dysfunction: Complex I deficiency leads to electron leak and superoxide formation
- Iron accumulation: Ferrocene-mediated Fenton chemistry generates hydroxyl radicals
- Neuroinflammation: Activated microglia produce nitric oxide and ROS
- Protein aggregation: Misfolded proteins overwhelm cellular defenses
Consequences:
- Lipid peroxidation and membrane damage
- DNA oxidation and mutation accumulation
- Protein carbonylation and function loss
- Axonal cytoskeletal disruption
The endoplasmic reticulum (ER) serves as the primary site for protein folding and calcium storage. In MSA, oligodendrocytes experience chronic ER stress due to the accumulation of misfolded α-synuclein and impaired protein quality control mechanisms [Zhang et al., 2023].
ER Stress Pathways:
- Unfolded Protein Response (UPR): Adaptive signaling to reduce protein load
- CHOP expression: Pro-apoptotic transcription factor
- Calcium dysregulation: ER calcium release disrupts cellular signaling
- Apoptosis: Long-term ER stress leads to cell death
The cellular protein quality control systems—comprising the ubiquitin-proteasome system (UPS) and autophagy-lysosome pathway (ALP)—are compromised in MSA. This impairment allows pathological proteins to accumulate and form inclusions.
Autophagy-Lysosome Pathway:
- Macroautophagy: Bulk degradation of cytoplasmic components
- Chaperone-mediated autophagy (CMA): Selective degradation of specific proteins
- Endosomal trafficking: Impaired in oligodendrocytes
Proteasomal Dysfunction:
- Reduced proteasome activity in affected regions
- Accumulation of ubiquitinated proteins
- Failure to clear pathological aggregates
Several therapeutic strategies target the core pathological mechanisms in MSA:
α-Synuclein-Targeted Therapies:
- Immunotherapy: Active vaccination and passive antibody administration
- Aggregation inhibitors: Small molecules preventing fibril formation
- Gene silencing: siRNA and antisense oligonucleotides targeting SNCA
- Strain-specific targeting: Development of MSA-selective interventions
Oligodendrocyte Protection:
- Myelin stabilizers: Compounds promoting myelin integrity
- Metabolic support: Enhancing oligodendrocyte energy production
- Iron chelation: Reducing oxidative stress from iron accumulation
- OPC activation: Stimulating remyelination from progenitor cells
While disease-modifying therapies remain under development, symptomatic treatments address key clinical manifestations:
Motor Symptoms:
- Levodopa/carbidopa: Dopaminergic replacement (limited efficacy)
- Dopamine agonists: Bromocriptine, ropinirole, pramipexole
- Physical therapy: Maintaining mobility and function
Autonomic Dysfunction:
- Orthostatic hypotension: Fludrocortisone, midodrine, compression stockings
- Urinary dysfunction: Oxybutynin, clean intermittent catheterization
Mitochondrial Protectants:
- Coenzyme Q10: Electron transport chain support
- Creatine: Energy reserve enhancement
- Mitochondrial peptides: Cell survival promotion
Anti-inflammatory Approaches:
- Minocycline: Microglial activation inhibition
- TNF-α inhibitors: Cytokine targeting
¶ Structure and Misfolding
Alpha-synuclein (α-syn) is a 140-amino acid protein encoded by the SNCA gene:
- N-terminal region (1-60 aa): Contains repeat motifs (KTKEGV) involved in membrane binding
- Central region (61-95 aa): Non-amyloid component (NAC) - hydrophobic, aggregation-prone
- C-terminal region (96-140 aa): Acidic, intrinsically disordered
In MSA, α-syn adopts a distinct conformational state:
- Phosphorylation: Predominantly at Ser129 (over 90% in GCIs vs. ~5% in physiological state)
- Truncation: C-terminal truncations facilitate aggregation
- Post-translational modifications: Ubiquitination, nitration
¶ GCI vs. Lewy Body Composition
| Feature |
GCI (MSA) |
Lewy Body (PD) |
| Main protein |
Phospho-α-syn |
Phospho-α-syn |
| Filament type |
Tubulin-rich |
Less tubulin |
| Ubiquitination |
Variable |
Prominent |
| Distribution |
Oligodendrocytes |
Neurons |
flowchart TD
A["Neuronal α-syn"] --> B["Release"]
B --> C["Extracellular Space"]
C --> D["Oligodendrocyte Uptake"]
D --> E["GCI Formation"]
F["Prion-Like Seed"] --> G["Template-Directed Misfolding"]
G --> H["Endogenous α-syn Conversion"]
E --> I["Myelin Dysfunction"]
I --> J["Axonal Degeneration"]
J --> K["Neuronal Loss"]
Exosomes play a critical role in neuron-to-oligodendrocyte alpha-synuclein transfer suzuki2024:
- Neuronal exosome release: Pathological alpha-synuclein packaged into exosomes
- Selective packaging: Disease-specific alpha-synuclein conformers preferentially released
- Uptake mechanisms: Oligodendrocytes internalize exosomes via clathrin-mediated endocytosis
- Seed transmission: Exosomal alpha-synuclein serves as potent aggregation seed
- Template-driven misfolding: Exogenous seeds trigger endogenous alpha-synuclein conversion
- Exosome release inhibitors: Targeting neuronal exosome biogenesis
- Neutralizing antibodies: Antibodies targeting exosomal alpha-synuclein conformers
- Endocytosis blockade: Inhibiting oligodendrocyte uptake pathways
Oligodendrocytes are the CNS myelin-producing cells:
- Myelination: Wrap axons with multilayer myelin sheaths
- Metabolic support: Provide lactate to axons through oligodendrocyte-axon coupling
- Ion homeostasis: Buffer extracellular potassium during action potentials
- Fast conduction: Enable saltatory conduction via node of Ranvier spacing
| Protein |
Function |
MSA Changes |
| MBP |
Myelin structural integrity |
Severely reduced |
| PLP |
Myelin stability |
Decreased |
| CNP |
Axonal metabolic support |
Reduced |
| MAG |
Axonal recognition |
Decreased |
| MOG |
Surface recognition |
Reduced |
Oligodendrocytes in MSA show heightened vulnerability:
- High iron content: Fenton chemistry generates oxidative stress
- High metabolic demand: Myelin maintenance requires extensive ATP
- Limited antioxidant capacity: Lower glutathione than neurons
- Slow turnover: Limited regenerative capacity
- Autophagy impairment: Accumulation of damaged proteins
The autophagy-lysosome pathway is critically impaired in MSA oligodendrocytes fellner2023:
- Autophagosome accumulation: LC3-II levels elevated, indicating blocked autophagic flux
- Lysosomal dysfunction: Cathepsin D activity reduced in affected regions
- GCI persistence: Impaired clearance leads to inclusion persistence
- mTOR pathway dysregulation: Hyperactivation inhibits normal autophagy
Oligodendrocytes contain the highest iron levels in the brain, making them particularly vulnerable to oxidative stress kiyosawa2024:
- Ferritin storage: Reduced ferritin leads to free iron accumulation
- Transferrin receptor: Decreased expression impairs iron uptake regulation
- Fenton chemistry: Free iron generates hydroxyl radicals via H₂O₂
- Lipid peroxidation: Iron-catalyzed oxidation damages myelin membranes
¶ TREM2 and Microglial Interactions
Microglial TREM2 plays a complex role in MSA nagai2024:
- TREM2 variants influence disease risk
- May have both protective and harmful effects
- Expression correlates with microglial density in affected regions
- Therapeutic targeting remains complex
The basal ganglia are severely affected in MSA:
flowchart TD
A["Cortex"] --> B["Striatum"]
B --> C["Internal Globus Pallidus"]
C --> D["Thalamus"]
D --> E["Motor Cortex"]
F["Substantia Nigra pars reticulata"] --> C
G["Oligodendrocyte Loss"] --> H["Myelin Degeneration"]
H --> I["Striatal Dysfunction"]
I --> J["Motor Pattern Generator Disruption"]
J --> K["Parkinsonism"]
Cerebellar involvement particularly in MSA-C:
- Deep cerebellar nuclei: Neuronal loss
- Cerebellar peduncles: White matter degeneration
- Purkinje cells: Secondary degeneration
- Brainstem connections: Multiple system involvement
- Dorsal motor nucleus of vagus: Autonomic dysfunction
- Nucleus tractus solitarius: Cardiovascular regulation
- Raphe nuclei: Serotonergic dysfunction
- Locus coeruleus: Noradrenergic deficits
Iron accumulation is a prominent feature of MSA pathogenesis, with particular emphasis on the basal ganglia and oligodendrocyte-rich regions. The mechanisms underlying iron dyshomeostasis include:
Iron Uptake Mechanisms:
- Transferrin receptor overexpression on oligodendrocytes
- Increased ferritin expression in affected regions
- DMT1 (divalent metal transporter 1) upregulation
Consequences of Iron Accumulation:
- Fenton reaction catalysis producing hydroxyl radicals
- Lipid peroxidation cascade
- Protein oxidation and aggregation
- Mitochondrial dysfunction amplification
Regional Distribution:
- Putamen: Most severely affected
- Red nucleus: Moderate deposition
- Globus pallidus: Significant accumulation
- Substantia nigra: Variable involvement
The antioxidant defense systems are compromised in MSA:
Primary Deficits:
- Reduced glutathione (GSH) levels in oligodendrocytes
- Decreased superoxide dismutase activity
- Impaired catalase function
Consequences:
- Vulnerable to oxidative damage
- Accelerated α-synuclein aggregation
- Lipid membrane peroxidation
Mitochondrial dysfunction creates a vicious cycle with oxidative stress:
- Complex I deficiency increases reactive oxygen species (ROS)
- ROS damages mitochondrial DNA and proteins
- Damaged mitochondria produce more ROS
- This amplifies cellular oxidative stress
See also: Iron dyshomeostasis in MSA pathogenesis
- Complex I deficiency: Observed in MSA brain tissue
- Oxidative phosphorylation: Reduced ATP production
- Mitochondrial DNA: Mutations accumulate
- Iron accumulation: Promotes ROS generation
- Glucose hypometabolism: PET studies show reduced uptake
- Lactate accumulation: Implies glycolytic dysfunction
- Creatine depletion: Energy reserve compromise
- Unfolded protein response: Activated in oligodendrocytes
- Calcium dysregulation: ER calcium stores perturbed
- Chaperone dysregulation: Protein folding capacity compromised
- TSPO PET: Increased binding in MSA brain
- Cytokine production: TNF-α, IL-1β, IL-6 elevated
- Complement activation: C1q, C3b deposition
- Phagocytic activity: Engulfment of debris
Microglia in MSA transition from a homeostatic to a disease-associated phenotype:
- Stage 1 DAM: TREM2-independent activation with downregulated homeostatic markers
- Stage 2 DAM: TREM2-dependent activation with upregulated phagocytic genes
- Functional consequences: Altered synaptic pruning, enhanced cytokine release
- Reactive astrogliosis: GFAP upregulation
- Dysfunction: Impaired potassium buffering
- Inflammation amplification: Cytokine and chemokine release
- Metabolic support failure: Reduced lactate shuttle to neurons
- Blood-brain barrier disruption: Permeability increases
- Pericyte dysfunction: Contributing to leakage
- Endothelial changes: Adhesion molecule upregulation
- Peripheral immune cell infiltration: CD4+ and CD8+ T cells in perivascular spaces
| Gene |
Function |
Association |
| SNCA |
α-synuclein |
Direct cause |
| COQ2 |
Coenzyme Q10 synthesis |
Risk factor |
| GBA |
Lysosomal enzyme |
Modifier |
| SCARB2 |
Lysosomal transporter |
Risk factor |
- Predominant features: Bradykinesia, rigidity, tremor
- Striatal pathology: Severe putaminal involvement
- Response to levodopa: Often poor
- Progression: More rapid than expected
- Predominant features: Ataxia, dysarthria, nystagmus
- Cerebellar pathology: Purkinje cell loss, white matter degeneration
- Disease course: Generally slower progression
- Features: Both parkinsonian and cerebellar signs
- Pathology: Widespread involvement
- Prognosis: Variable, often intermediate
- Level 1: Possible MSA (one cardinal feature)
- Level 2: Probable MSA (autonomic failure + one other)
- Level 3: Definite MSA (neuropathological confirmation)
- Early falls: Within 3 years of onset
- Poor levodopa response: Despite adequate dosing
- Rapid progression: Disability within 5 years
- Symmetric parkinsonism: More than unilateral
| Condition |
Distinguishing Features |
| PD |
Asymmetric onset, levodopa response |
| PSP |
Vertical gaze palsy, early falls |
| CBD |
Asymmetric apraxia, cortical signs |
| DLB |
Fluctuating cognition, visual hallucinations |
| Target |
Approach |
Status |
| α-synuclein |
Immunotherapies |
Phase 1/2 trials |
| α-synuclein |
Aggregation inhibitors |
Preclinical |
| Oligodendrocytes |
Myelin protectors |
Investigational |
| Autophagy |
Enhancement strategies |
Preclinical |
- Motor symptoms: Levodopa, dopamine agonists
- Autonomic dysfunction: Midodrine, fludrocortisone
- Cerebellar signs: Adaptive devices, physical therapy
- Sleep disorders: Clonazepam for REM sleep behavior disorder
- Mesenchymal stem cells: Neuroprotective potential
- Gene therapy: Targeting specific pathways
- Neurotrophic factors: Promoting oligodendrocyte survival
| Marker |
Source |
Significance |
| α-synuclein oligomers |
CSF |
Disease-specific |
| Total α-synuclein |
CSF |
Decreased in MSA |
| Neurofilament light chain |
CSF/Serum |
Progression marker |
| Tau protein |
CSF |
Differential diagnosis |
- MRI: Hot cross bun sign, atrophy patterns
- DTI: White matter tract integrity
- PET: Neuroinflammation (TSPO), glucose metabolism
- SWI: Iron deposition mapping
- Immunohistochemistry: α-syn (Ser129), ubiquitin, p62
- Silver stains: GCI visualization
- Electron microscopy: Filament ultrastructure
- Confocal microscopy: Colocalization studies
- Proteomics: GCI protein composition
- RNA-seq: Transcriptomic changes
- Single-cell sequencing: Cell-type specific analysis
- Spatial transcriptomics: Regional patterns
- What triggers α-synuclein pathology in oligodendrocytes?
- Why are oligodendrocytes specifically vulnerable?
- What determines clinical subtype (MSA-P vs. MSA-C)?
- Can remyelination be achieved in established disease?
- What is the optimal biomarker for clinical trials?
- Early detection: Identify prodromal disease
- Mechanistic understanding: Oligodendrocyte-specific factors
- Therapeutic targets: Disease-modifying interventions
- Biomarker validation: Surrogate endpoints for trials
The pattern of neurodegeneration in MSA follows characteristic regional distributions that correlate with clinical phenotypes and provide insights into disease progression.
Brainstem Regions:
The brainstem exhibits early and severe involvement in MSA, with particular vulnerability of autonomic centers. The dorsal motor nucleus of the vagus (DMV) shows prominent neuronal loss and GCI formation, contributing to the early autonomic dysfunction characteristic of the disease. The locus coeruleus, the primary source of noradrenergic innervation, demonstrates significant pathology affecting sympathetic regulation. The substantia nigra pars compacta experiences moderate neuronal loss, though generally less severe than in Parkinson's disease, while the pars reticulata shows more pronounced involvement affecting motor output pathways.
Basal Ganglia:
The striatum, comprising the caudate nucleus and putamen, undergoes substantial degeneration in MSA-P. The posterior putamen shows the most severe involvement, correlating with the poor levodopa response observed in this variant. The globus pallidus externus and internus both exhibit pathology, with the internal segment showing particular involvement in generating parkinsonian features. The subthalamic nucleus demonstrates variable involvement, and its preservation may influence the response to certain therapeutic interventions.
Cerebellar System:
The cerebellar involvement in MSA-C centers on the cerebellar hemispheres and their connecting pathways. The Purkinje cells, the sole output neurons of the cerebellar cortex, undergo significant degeneration leading to disinhibition of the deep cerebellar nuclei. The middle cerebellar peduncle shows prominent white matter degeneration on MRI, appearing as hyperintense signals on FLAIR imaging. The dentate nucleus, the major output structure of the cerebellum, demonstrates neuronal loss and gliosis, contributing to the ataxic features characteristic of MSA-C.
White Matter Tracts:
Beyond the focal gray matter involvement, MSA affects major white matter tracts throughout the brain. The pontocerebellar fibers, connecting the pons to the cerebellum, show particular vulnerability, giving rise to the characteristic "hot cross bun" sign on MRI. The corpus callosum demonstrates progressive degeneration, while the corticospinal tracts show variable involvement. The olfactory tract remains relatively preserved in MSA, helping to distinguish this condition from Parkinson's disease where olfactory loss is prominent.
The progression of MSA can be conceptualized through a staging system that reflects the anatomical spread of pathology:
Stage 1 (Pre-motor):
Regional GCI formation in brainstem autonomic nuclei, particularly the DMV and nucleus tractus solitarius. Minimal neuronal loss at this stage. Autonomic symptoms may be present but motor features absent.
Stage 2 (Early motor):
Spread of pathology to pontine nuclei and cerebellar white matter. Beginning of striatal involvement. emergence of motor symptoms correlating with the regional distribution of pathology.
Stage 3 (Established disease):
Widespread GCI formation throughout the brainstem, basal ganglia, and cerebellar system. Significant neuronal loss in affected regions. Clear clinical syndrome of either MSA-P or MSA-C with autonomic failure.
Stage 4 (Advanced disease):
End-stage pathology with near-complete degeneration of vulnerable regions. Cortical involvement in some cases. Severe disability and functional decline.